Drotrecogin alpha (activated) in two patients with the hantavirus cardiopulmonary syndrome

Canadian Respiratory Journal

Volumn 13, Issue 5, 2006, Pages 272-274

  McDermid, Robert Charles ^a,b   Gibney, R T Noel ^a   Brisebois, Ronald J ^a   Skjodt, Neil M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Drotrecogin; Hantavirus; Respiratory failure; Septic shock

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFOTAXIME; CREATININE; DOBUTAMINE; DROTRECOGIN; FLUDROCORTISONE; HYDROCORTISONE; NORADRENALIN; TOBRAMYCIN; VANCOMYCIN; VASOACTIVE AGENT; VASOPRESSIN;

ADULT; ARTICLE; CASE REPORT; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG MEGADOSE; FEMALE; HANTAVIRUS CARDIOPULMONARY SYNDROME; HEADACHE; HEART DISEASE; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; KIDNEY FAILURE; LOW DRUG DOSE; MALAISE; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; SEPTIC SHOCK; SIN NOMBRE VIRUS; SINGLE DRUG DOSE; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; VOMITING;

EID: 33749337080     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/359891     Document Type: Article

References (10)

1. From the Centers for Disease Control and Prevention. Infectious diseases update: Outbreak, hantavirus infection - southwestern United States, 1993. JAMA 1993;270:25.
2. Frampton JW, Lanser S, Nichols CR. Sin Nombre virus infection in 1959. Lancet 1995;346:781-2.
3. Boroja M, Barrie JR, Raymond GS. Radiographic findings in 20 patients with Hantavirus pulmonary syndrome correlated with clinical outcome. AJR Am J Roentgenol 2002;178:159-63.
4. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
5. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-92.
6. Mori M, Rothman AL, Kurane I, et al. High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. J Infect Dis 1999;179:295-302.
7. Mertz GH, Hjelle BL, Bryan RT. Hantavirus infection. Dis Mon 1998;44:85-138.
8. Wimer BM. Implications of the analogy between recombinant cytokine toxicities and manifestations of hantavirus infections. Cancer Biother Radiopharm 1998;13:193-207.
9. Hallin GW, Simpson SQ, Crowell RE, et al. Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit Care Med 1996;24:252-8.
10. Crowley MR, Katz RW, Kessler R, et al. Successful treatment of adults with severe Hantavirus pulmonary syndrome with extracorporeal membrane oxygenation. Crit Care Med 1998;26:409-14. (Erratum in 1998;26:806).